Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati sponsors 571 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 372 completed. 38 of these trials are in Phase 3-4 (later-stage) and 140 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 13 trials.
Trial Pipeline
571 total, page 2 of 12
Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders
NCT06227780
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
NCT05580601
Supraspinal Processing of Sensory Aspects of Pain
NCT05814497
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
NCT05579639
Overlapping Pain Trajectory Study
NCT05752396
Evaluating Additive Effects of Including Canines in Regulating Together
NCT05803343
Setting Families on a Positive Path to Recovery After Pediatric TBI: Road-to-Recovery
NCT05622461
Study of Gastric Motility in Eosinophilic Gastritis
NCT05229432
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
NCT05501756
NO During CPB in Neonates to Reduce Risk of AKI
NCT04216927
Comparison of a Demand Oxygen Delivery
NCT06609694
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
NCT06560242
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
NCT05957549
Natural History of Cerebral Palsy Prospective Study
NCT05576948
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
NCT05556642
Animal Assisted Therapy After Pediatric Brain Injury: Mediators and Moderators of Treatment Response.
NCT05250180
BEGIN Novel ImagiNG Biomarkers
NCT05517655
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
NCT05750498
Motor Training for Infants With Cerebral Palsy
NCT04886895
INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
NCT05277272
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT04098445
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
NCT05012631
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
NCT07477197
Migraine Manager (R01)
NCT04567355
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
NCT04580368
Mind Body Balance for Pediatric Migraine
NCT04715685
Regional Phenotyping of CF and Non-CF Bronchiectasis
NCT04793867
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
NCT04230356
Evaluating Treatment of ADHD in Children with Down Syndrome
NCT04219280
Use of Hyperpolarized 129Xe MR Lung Imaging in Infants
NCT04995562
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
NCT04093986
Suicide Treatment Alternatives for Teens
NCT04089254
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
NCT03847467
Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics
NCT04991389
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
NCT03826992
Markers of Trajectory in Pediatric CRPS
NCT03838107
MRI in BPD Subjects
NCT03657693
RASopathy Biorepository
NCT04395495
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
NCT03175471
Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia
NCT02986087
The Congenital Dyserythropoietic Anemia Registry (CDAR)
NCT02964494
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Third Party Viral Specific T-cells (VSTs)
NCT02532452
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
NCT02523118
Identification of Biomarkers for Patients with Vascular Anomalies
NCT03001180
A National Registry For Pulmonary Alveolar Proteinosis
NCT02461615
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
NCT02316379
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
NCT02272049
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 54 |
| Phase 3 | 15 |
| Phase 4 | 23 |
Therapeutic Areas
What the Pipeline for Children's Hospital Medical Center, Cincinnati Shows
According to the ClinicalTrials.gov registry, Children's Hospital Medical Center, Cincinnati is linked to 571 US clinical trials across every stage of research activity. Of those, 106 studies are currently recruiting, about 19% of the sponsor's indexed portfolio, and 372 are already marked complete, representing roughly 65% of the total.
The phase mix for Children's Hospital Medical Center, Cincinnati reports 38 late-stage studies (Phase 3 and Phase 4 combined) and 140 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Children's Hospital Medical Center, Cincinnati is Autism Spectrum Disorder with 13 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.